Molecular Vision: Inagaki, Mol Vis 2011; 17:598-606. Table 1

Table 1. Clinical characteristics of chronic graft versus host disease patients with corneal perforation.

Case number	Case 1	Case 2	Case 3	Case 4
Age (Years), sex	62, M	21, M	70, M	56, F
Underlying disease	AML (M4)	AML (M0)	AML (M4)	CML
Type of treatment	Allo-PBSCT	mini BMT	Allo-PBSCT	mini BMT
Onset of dry eye (month)	6	4	4	N.A.
Onset of corneal perforation (month)	17	20	30	8
Schirmer Test (mm)	1	0	4	10
Fluorescein Score (9 points)	9	9	3	3
MGD score (3 points)	Unknown	3	3	Unknown
External bacterial flora culture	MRSA	Trichosporon spp.	MRSA	negative
Entropion	−	+	+	−
Corneal neovascularization	−	+	+	−
Topical drops (corticosteroid)	+ (1 day)*	+ (5 years)**	+ (3 weeks)***	−
Topical drops (NSAIDS)	−	−	+ (3 weeks)§	+ (4 months)¶
Oral corticosteroids (PSL)	+ (3 months)	+ (15 mg) (6 months)	+ (10 mg) (> 2 years)	+ (> 20 mg) (2 months)

AML, acute myeloid leukemia; CML, chronic myeloid leukemia; allo-PBSCT, allogeneic peripheral blood stem cell transplantation; MGD, meibomian gland dysfunction; MRSA, methicillin-resistant Staphylococcus aureus; mini BMT, mini bone marrow transplantation, reduced intensity of conditioning regimen for hematopoietic stem cell transplantation; NSAIDS, non-steroidal anti-inflammatory drugs; *, dexamethasone sodium phosphate; **, 0.02% fluorometholone; ***, 0.1% fluorometholone; §, dicrofenac sodium;¶, bromfenac sodium, Topical corticosteroids were used 4 times per day; Topical NSAIDS were used 2 times per day. The dose (per day) and duration of oral corticosteroid were shown in the table. PSL, predonisolone; mo, months.